trametinib
Selected indexed studies
- Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. (N Engl J Med, 2024) [PMID:38899716]
- Dabrafenib plus Trametinib in Pediatric Glioma with BRAF V600 Mutations. (N Engl J Med, 2023) [PMID:37733309]
- Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial. (Lancet, 2022) [PMID:35123694]
_Worker-drafted node — pending editorial review._
Connections
trametinib is a side effect of
Sources
- Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. (2024) pubmed
- Dabrafenib plus Trametinib in Pediatric Glioma with BRAF V600 Mutations. (2023) pubmed
- Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. (2017) pubmed
- Dabrafenib, alone or in combination with trametinib, in BRAF V600-mutated pediatric Langerhans cell histiocytosis. (2023) pubmed
- Efficacy and Safety of Trametinib Monotherapy or in Combination With Dabrafenib in Pediatric BRAF V600-Mutant Low-Grade Glioma. (2023) pubmed
- Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC: Updated 5-Year Survival Rates and Genomic Analysis. (2022) pubmed
- Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial. (2022) pubmed
- Trametinib. (2014) pubmed
- Trametinib (GSK1120212). (2018) pubmed
- Targeting MXD1 sensitises pancreatic cancer to trametinib. (2025) pubmed